Here you will find articles that keep you up to date on the newest AML research that AML experts are recruiting for. AML research studies called clinical trials are all about drug development. Drugs must go through many phases of testing to receive FDA approval in order to be prescribed to patients by doctors. Joining a clinical trial for your AML has the potential to provide you with cutting-edge treatment that is not yet widely available to the general public.
In addition to drug development, AML research aims to answer important questions like "what is AML?", "what causes AML?", "is AML genetic?" and "how do we improve AML survival?"
There are over 300 AML research trials actively recruiting patients, which is more than any other leukemia. These articles will keep you informed on the latest clinical trials that are recruiting and the types of new drug therapies that are being studied for the treatment of AML.
AML Clinical Trials—January 20, 2022
At the 2021 ASH conference, Dr. Sallman from Moffitt Cancer Center in Florida presents his abstract on the long-term follow-up of Eprenetapopt (APR-246) for p53 mutant MDS and AML patients with ≤ 30% blasts. He hypothesizes that with this new therapy, patients may be able to get treatment pre and post-transplant which could finally lead to improved outcomes and potentially a cure for this difficult-to-treat subset of patients.
AML Clinical Trials—January 19, 2022
Dr. Mannis describes the oral abstact that he presented at the ASH 2021 annual meeting revealing that a new oral decitabine medication combined with another oral medication called venetoclax appears safe, well tolerated and just as effective as IV decitabine. It is Dr. Mannis's hope that this drug combination will become FDA approved in the near future and become the new standard of care for treating older adults with acute myeloid leukemia.
AML Clinical Trials—January 13, 2022
Dr. Chen reports on his research at ASH which found that preliminary results indicate venetoclax plus decitabine is an effective, lower-intensity regimen that is well tolerated for young adults with newly diagnosed adverse-risk AML, producing high rates of complete response, low rates of infections, and low rates of early death.
AML Clinical Trials—January 6, 2022
A new natural killer cell therapy called CYNK-001 has been given fast track designation by the FDA. Learn more about the phase 1 open clinical trial evaulating this new therapy in those with primary or secondary MRD positive AML.
AML Clinical Trials—December 20, 2021
Results presented from the AGILE trial at the 2021 ASH conference revealed that the combination of ivosidenib and azacitidine in those with newly diagnosed IDH-1 mutated AML who cannot undergo intensive induction chemotherapy produced an average overall survival that was approximately three times longer than patients who were treated with azacitidine alone.
AML Clinical Trials—December 16, 2021
Dr. Sallman, AML expert from Moffitt Cancer Center in Tampa, Florida discusses with us his phase 1/1b safety study of PRGN-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
AML Clinical Trials—December 1, 2021
A clinical trial conducted at the University of North Carolina Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab (Keytruda) benefited patients with resistant or relapsed AML.
AML Clinical Trials—November 18, 2021
Clinical trials are critical to finding a cure for every person with acute myeloid leukemia but yet only a small percentage of patients actually enroll and participate. This is due to a variety of factors but fear often plays a role in one's decision not to participate. Learn about common clinical trial myths in order to empower your decision making regarding participation.
AML Clinical Trials—October 11, 2021
The combination of ficlatuzumab and cytarabine could provide an alternative therapeutic option for patients with relapsed or refractory AML that has already shown positive results in an early clinical trial.
AML Clinical Trials—September 23, 2021
VOR33, a cell therapy candidate intended to replace the standard of care in stem cell transplant, receives fast track designation from the FDA, making this therapy eligible for priority review and accelerated approval if certain conditions are met. This designation demonstrates the FDA's acknowledgment that this engineered stem cell product could fulfill a major unmet medical need for those with AML at a high risk of relapse.